Focus article

What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension

EuroIntervention 2014;9:1027-1035. DOI: 10.4244/EIJV9I9A175

Konstantinos Tsioufis
Costas Tsioufis1*, MD; Felix Mahfoud2, MD; Giuseppe Mancia3, MD, PhD; Josep Redon4, MD; Bruno Damascelli5,6, MD; Thomas Zeller7, MD; Roland E. Schmieder8, MD
1. First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece; 2. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Ge

Percutaneous catheter-based transluminal renal denervation (RDN) has emerged as a new approach to achieve sustained blood pressure reduction in patients with drug-resistant hypertension. Experts from ESH and ESC in their rece

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

ablation devicesrenal denervationresistant hypertension
Read next article
Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes

Latest news